> > >

Rebinyn® Travel Case

With a Rebinyn® Travel Case, your patients can take their factor along. This portable, reusable travel case helps store other supplies conveniently, whether patients are traveling or at home.

US19REB00062

To request a Travel Case,

please contact a Novo Nordisk representative.

Additional Information

We’ve created additional, easy-to-share resources to address your questions about Rebinyn®.

Choose from these materials:

Patient Welcome Kit

Rebinyn® Patient Brochure

GET THE LATEST UPDATES ON REBINYN®

Website link

GET THE LATEST UPDATES ON REBINYN®

   Register Today   

Also Available from Novo Nordisk:

NovoSevenRT® logo

Visit website
Prescribing Information

NovoSevenRT® logo

Visit website
Prescribing Information

Esperoct® logo

Visit website
Prescribing Information

Esperoct® logo

Visit website
Prescribing Information

Novoeight® logo

Visit website
Prescribing Information

Novoeight® logo

Visit website
Prescribing Information

Tretten® logo

Visit website
Prescribing Information

Tretten® logo

Visit website
Prescribing Information

Selected Important Safety Information

Contraindications

  • Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.

Warnings and Precautions

Hypersensitivity reactions, including anaphylaxis, may occur. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic or anaphylactic type reactions occur and initiate appropriate treatment.

Indications and Usage

Rebinyn®, Coagulation Factor IX (Recombinant), GlycoPEGylated, is a recombinant DNA derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes and perioperative management of bleeding.

Limitations of Use: Rebinyn® is not indicated for routine prophylaxis or for immune tolerance induction in patients with hemophilia B.

Important Safety Information

Contraindications

  • Rebinyn® is contraindicated in patients with a known hypersensitivity to Rebinyn® or its components, including hamster proteins.

Warnings and Precautions

  • Hypersensitivity reactions, including anaphylaxis, may occur. Signs may include angioedema, chest tightness, difficulty breathing, wheezing, urticaria, and itching. Discontinue Rebinyn® if allergic or anaphylactic-type reactions occur and initiate appropriate treatment.
  • Development of neutralizing antibodies (inhibitors) to Factor IX  may occur. Monitor patients for development of Factor IX inhibitors if bleeding is not controlled with the recommended dose of Rebinyn® or if expected Factor IX activity plasma levels are not attained. Factor IX activity assay results may vary with the type of activated partial thromboplastin time reagent used.
  • The use of Factor IX-containing products has been associated with thrombotic complications. Monitor for thrombotic and consumptive coagulopathy when administering Rebinyn® to patients with liver disease, post-operatively, to newborn infants, or to patients at risk of thrombosis or disseminated intravascular coagulation (DIC).
  • Nephrotic syndrome has been reported following immune tolerance induction therapy with Factor IX products in hemophilia B patients with Factor IX inhibitors, often with a history of allergic reactions to Factor IX. The safety and efficacy of using Rebinyn® for immune tolerance induction have not been established.

Adverse Reactions

  • The most common adverse reactions reported in clinical trials (≥1%) were itching and injection site reactions.
  • Animals administered repeat doses of Rebinyn® showed accumulation of PEG in the choroid plexus. The potential clinical implications of these animal findings are unknown.

Please click here for Prescribing Information.